HOME  >  Pipelines




GM103 is an oncolytic adenovirus that induces robust and systemic tumor-specific immune response and simultaneously inhibits tumor angiogenesis

Indication: Metastatic lung and liver cancer

Development stage: preparing phase 1 clinical trial

Description 1. GM103 induces robust and tumor-specific systemic immune response to exert potent antitumor effect against both the primary and metastatic tumor lesions 2. GM103 is capable of inducing regression of tumors with extremely high tumor burden at the time of treatment 3. GM103 exerts synergistic antitumor effect in combination with immune checkpoint inhibitors

GM103 Data